77 related articles for article (PubMed ID: 7511163)
1. 5 beta-Methyl-14 beta-(p-nitrocinnamoylamino)-7,8-dihydromorphinone and its corresponding N-cyclopropylmethyl analog, N-cyclopropylmethylnor-5 beta-methyl-14 beta-(p-nitrocinnamoylamino)- 7,8-dihydromorphinone: mu-selective irreversible opioid antagonists.
Jiang Q; Sebastian A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1994 Mar; 268(3):1107-13. PubMed ID: 7511163
[TBL] [Abstract][Full Text] [Related]
2. Preventing morphine antinociceptive tolerance by irreversible mu opioid antagonists before the onset of their antagonism.
Jiang Q; Seyed-Mozaffari A; Sebastian A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1995 May; 273(2):680-8. PubMed ID: 7752070
[TBL] [Abstract][Full Text] [Related]
3. Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.
McLaughlin JP; Hill KP; Jiang Q; Sebastian A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1999 Apr; 289(1):304-11. PubMed ID: 10087018
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological study of 14 beta-(thioglycolamido)-7,8-dihydro-N(cyclopropylmethyl)-normor phinone (N-CPM-TAMO).
Jiang Q; Seyed-Mozaffari A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1993 Mar; 264(3):1021-7. PubMed ID: 7680715
[TBL] [Abstract][Full Text] [Related]
5. 14 beta-Chlorocinnamoylamino derivatives of metopon: long-term mu-opioid receptor antagonists.
McLaughlin JP; Sebastian A; Archer S; Bidlack JM
Eur J Pharmacol; 1997 Feb; 320(2-3):121-9. PubMed ID: 9059844
[TBL] [Abstract][Full Text] [Related]
6. Antinociceptive properties of two alkylating derivatives of morphinone: 14 beta-(thioglycolamido)-7,8-dihydromorphinone (TAMO) and 14 beta-(bromoacetamido)-7,8-dihydromorphinone (H2BAMO).
Jiang Q; Seyed-Mozaffari A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1992 Aug; 262(2):526-31. PubMed ID: 1380079
[TBL] [Abstract][Full Text] [Related]
7. N-cyclobutylmethyl analog of normorphinone, N-CBM-TAMO: a short-term opioid agonist and long-term Mu-selective irreversible opioid antagonist.
Xu JY; Seyed-Mozaffari A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1996 Nov; 279(2):539-47. PubMed ID: 8930155
[TBL] [Abstract][Full Text] [Related]
8. 5 beta-Methyl-14 beta-(p-nitrocinnamoylamino)-7,8-dihydromorphinone: a long-lasting mu-opioid receptor antagonist devoid of agonist properties.
Jiang Q; Sebastian A; Archer S; Bidlack JM
Eur J Pharmacol; 1993 Jan; 230(1):129-30. PubMed ID: 7679076
[TBL] [Abstract][Full Text] [Related]
9. Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse.
Mizoguchi H; Spaulding A; Leitermann R; Wu HE; Nagase H; Tseng LF
J Pharmacol Exp Ther; 2003 Jul; 306(1):394-400. PubMed ID: 12721333
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment with pertussis toxin differentially modulates morphine- and beta-endorphin-induced antinociception in the mouse.
Tseng LF; Collins KA
J Pharmacol Exp Ther; 1996 Oct; 279(1):39-46. PubMed ID: 8858973
[TBL] [Abstract][Full Text] [Related]
11. Antinociceptive evaluation of 14 beta-(bromoacetamido)-7,8-dihydro- N(cyclopropylmethyl)-normorphinone in mice.
Jiang Q; Seyed-Mozaffari A; Archer S; Bidlack JM
Eur J Pharmacol; 1993 Aug; 240(2-3):201-6. PubMed ID: 7694857
[TBL] [Abstract][Full Text] [Related]
12. Antinociceptive profile of biphalin, a dimeric enkephalin analog.
Horan PJ; Mattia A; Bilsky EJ; Weber S; Davis TP; Yamamura HI; Malatynska E; Appleyard SM; Slaninova J; Misicka A
J Pharmacol Exp Ther; 1993 Jun; 265(3):1446-54. PubMed ID: 8389867
[TBL] [Abstract][Full Text] [Related]
13. N-acetyl beta-endorphin-(1-31) and substance P regulate the supraspinal antinociception mediated by mu opioid and alpha-2 adrenoceptors but not by delta opioid receptors in the mouse.
Sánchez-Blázquez P; Garzón J
J Pharmacol Exp Ther; 1993 May; 265(2):835-43. PubMed ID: 7684446
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioral assays.
Zernig G; Burke T; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1996 Oct; 279(1):23-31. PubMed ID: 8858971
[TBL] [Abstract][Full Text] [Related]
15. Delta-1 opioid receptor-mediated antinociceptive properties of a nonpeptidic delta opioid receptor agonist, (-)TAN-67, in the mouse spinal cord.
Tseng LF; Narita M; Mizoguchi H; Kawai K; Mizusuna A; Kamei J; Suzuki T; Nagase H
J Pharmacol Exp Ther; 1997 Feb; 280(2):600-5. PubMed ID: 9023269
[TBL] [Abstract][Full Text] [Related]
16. Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice.
Burke TF; Woods JH; Lewis JW; Medzihradsky F
J Pharmacol Exp Ther; 1994 Nov; 271(2):715-21. PubMed ID: 7965787
[TBL] [Abstract][Full Text] [Related]
17. Metopon and two unique derivatives: affinity and selectivity for the multiple opioid receptors.
McLaughlin JP; Nowak D; Sebastian A; Schultz AG; Archer S; Bidlack JM
Eur J Pharmacol; 1995 Dec; 294(1):201-6. PubMed ID: 8788432
[TBL] [Abstract][Full Text] [Related]
18. SNF9007: a novel analgesic that acts simultaneously at delta 1, delta 2 and mu opioid receptors.
Williams CL; Rosenfeld GC; Dafny N; Fang SN; Hruby VJ; Bowden G; Cullinan CA; Burks TF
J Pharmacol Exp Ther; 1994 May; 269(2):750-5. PubMed ID: 8182541
[TBL] [Abstract][Full Text] [Related]
19. Spinal involvement of both dynorphin A and Met-enkephalin in the antinociception induced by intracerebroventricularly administered bremazocine but not morphine in the mouse.
Tseng LF; Collins KA
J Pharmacol Exp Ther; 1993 Sep; 266(3):1430-8. PubMed ID: 8103794
[TBL] [Abstract][Full Text] [Related]
20. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
